CAMBRIDGE–Harbour BioMed announced that China’s National Medical Products Administration (NMPA) has accepted an Investigational New Drug (IND) application for LET003, an experimental antibody therapy developed using artificial intelligence to treat overweight and obesity.
The application marks a regulatory milestone for LET003, the company’s first drug candidate developed using its proprietary Hu-mAtrIx AI platform.
The investigational treatment is designed to reduce body fat while preserving or increasing lean muscle mass, addressing a challenge associated with some existing weight-loss medications.
LET003 is a monoclonal antibody that targets two activin receptors, ACVR2A and ACVR2B, which are involved in regulating muscle development, fat metabolism and overall body composition.
By blocking these receptors, Harbour BioMed aims to develop a treatment that could complement existing obesity medications, including glucagon-like peptide-1 (GLP-1) therapies.
GLP-1 drugs have significantly changed obesity treatment by helping patients achieve substantial weight loss. However, some of that weight reduction can involve the loss of lean body mass, raising concerns about muscle preservation and long-term metabolic health.
Harbour BioMed believes its approach could help address this issue by promoting fat reduction while maintaining muscle mass.
In preclinical studies, LET003 demonstrated favorable pharmacokinetic properties compared with several competing experimental molecules, according to the company.
When combined with semaglutide, a GLP-1-based medication, LET003 increased fat reduction while helping preserve lean mass in preclinical animal models.
The company also reported that LET003 produced effects on lean mass at lower doses comparable to those achieved with higher doses of bimagrumab, another antibody treatment being investigated for its effects on body composition.
The findings suggest potential benefits from combining LET003 with established weight-loss therapies, although its safety and effectiveness in humans have not yet been established.
“NMPA’s acceptance of the IND application for LET003 marks a significant milestone for Harbour BioMed. LET003 leads the exciting progress in our obesity portfolio in addition to being our first AI-enabled candidate developed using our proprietary Hu-mAtrIx™ platform,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
“We look forward to advancing LET003 through clinical development and further realizing the potential of our AI-enabled drug discovery capabilities to address significant unmet medical needs,” Wang added.
The acceptance of the IND application represents a step toward clinical testing but does not constitute regulatory approval of the drug.
Harbour BioMed plans to evaluate LET003 in human clinical studies to determine its safety, tolerability and potential effectiveness in treating overweight and obesity.
The company is positioning the therapy within an emerging area of obesity research focused on improving body composition rather than measuring treatment success solely through reductions in body weight.
“Obesity treatment is evolving beyond weight reduction alone toward improving body composition and achieving more sustainable health outcomes,” said Dr. Bob Zhang, President of the Metabolic Disease Franchise at Harbour BioMed.
“By targeting ACVR2A and ACVR2B, LET003 is designed to address an important challenge in overweight or obesity management: preserving or improving lean mass while enhancing fat reduction. We believe LET003 has the potential to offer a differentiated therapeutic approach and look forward to evaluating its potential in clinical development,” Zhang added.
Obesity is a chronic disease associated with an increased risk of several serious medical conditions, including type 2 diabetes, cardiovascular disease and certain cancers.
While newer weight-loss medications have improved treatment options, researchers continue to investigate therapies that could help patients maintain muscle mass and achieve more sustainable improvements in metabolic health.
Harbour BioMed’s Hu-mAtrIx platform uses artificial intelligence to support the discovery and development of antibody-based medicines.
LET003 is the first dual ACVR2A/ACVR2B-blocking antibody developed through the platform.
The company, which operates in Cambridge, Massachusetts, Rotterdam, Netherlands, and Shanghai, China, develops antibody therapeutics across several disease areas, including immunology, oncology and metabolic disorders.
The next stage of LET003’s development will focus on clinical evaluation to determine whether the benefits observed in preclinical studies can be reproduced in patients.


